Company Registration No. 06589980 (England and Wales)
REACH OUT CLINICAL LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
75 High Street
Boston
Lincolnshire
PE21 8SX
REACH OUT CLINICAL LIMITED
CONTENTS
Page
Company information
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
REACH OUT CLINICAL LIMITED
BALANCE SHEET
AS AT 30 NOVEMBER 2025
30 November 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
1,664
1,957
Current assets
Debtors
5
21,670
31,338
Cash at bank and in hand
27,593
33,145
49,263
64,483
Creditors: amounts falling due within one year
6
(49,025)
(39,412)
Net current assets
238
25,071
Total assets less current liabilities
1,902
27,028
Provisions for liabilities
(371)
(371)
Net assets
1,531
26,657
Capital and reserves
Called up share capital
7
100
100
Profit and loss reserves
1,431
26,557
Total equity
1,531
26,657

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

REACH OUT CLINICAL LIMITED
BALANCE SHEET (CONTINUED)
AS AT 30 NOVEMBER 2025
30 November 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 6 July 2026 and are signed on its behalf by:
Dr Nazeer Dahar
Director
Company registration number 06589980 (England and Wales)
REACH OUT CLINICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 3 -
1
Accounting policies
Company information

Reach Out Clinical Limited is a private company limited by shares incorporated in England and Wales. The registered office is 257 Sleaford Road, Boston, Lincolnshire, PE21 7PQ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account settlement discounts and rebates.

Revenue from services provided is recognised when it is probable that associated economic benefits will flow to the company.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings and equipment
15% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

REACH OUT CLINICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

REACH OUT CLINICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
3
3
4
Tangible fixed assets
Fixtures, fittings and equipment
£
Cost
At 1 December 2024 and 30 November 2025
5,350
Depreciation and impairment
At 1 December 2024
3,393
Depreciation charged in the year
293
At 30 November 2025
3,686
Carrying amount
At 30 November 2025
1,664
At 30 November 2024
1,957
REACH OUT CLINICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 6 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
20,484
17,977
Corporation tax recoverable
1,181
-
0
Other debtors
5
13,361
21,670
31,338
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
37,636
30,367
Corporation tax
-
0
1,181
Other taxation and social security
-
0
227
Other creditors
9,469
5,837
Accruals and deferred income
1,920
1,800
49,025
39,412
7
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A Shares of £1 each
40
40
40
40
Ordinary B Shares of £1 each
20
20
20
20
Ordinary C Shares of £1 each
40
40
40
40
100
100
100
100
2025-11-30 2024-12-01 false false false 06 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mrs Humera Dahar Dr Jazib Dahar Miss Erum Dahar Mr Hunain A Dahar Dr Nazeer Dahar 06589980 2024-12-01 2025-11-30 06589980 2025-11-30 06589980 2024-11-30 06589980 core:FurnitureFittings 2025-11-30 06589980 core:FurnitureFittings 2024-11-30 06589980 core:CurrentFinancialInstruments core:WithinOneYear 2025-11-30 06589980 core:CurrentFinancialInstruments core:WithinOneYear 2024-11-30 06589980 core:ShareCapital 2025-11-30 06589980 core:ShareCapital 2024-11-30 06589980 core:RetainedEarningsAccumulatedLosses 2025-11-30 06589980 core:RetainedEarningsAccumulatedLosses 2024-11-30 06589980 core:ShareCapitalOrdinaryShareClass1 2025-11-30 06589980 core:ShareCapitalOrdinaryShareClass1 2024-11-30 06589980 core:ShareCapitalOrdinaryShareClass2 2025-11-30 06589980 core:ShareCapitalOrdinaryShareClass2 2024-11-30 06589980 core:ShareCapitalOrdinaryShareClass3 2025-11-30 06589980 core:ShareCapitalOrdinaryShareClass3 2024-11-30 06589980 core:ShareCapitalOrdinaryShares 2025-11-30 06589980 core:ShareCapitalOrdinaryShares 2024-11-30 06589980 bus:Director5 2024-12-01 2025-11-30 06589980 core:FurnitureFittings 2024-12-01 2025-11-30 06589980 2023-12-01 2024-11-30 06589980 core:FurnitureFittings 2024-11-30 06589980 core:CurrentFinancialInstruments 2025-11-30 06589980 core:CurrentFinancialInstruments 2024-11-30 06589980 bus:OrdinaryShareClass1 2024-12-01 2025-11-30 06589980 bus:OrdinaryShareClass2 2024-12-01 2025-11-30 06589980 bus:OrdinaryShareClass3 2024-12-01 2025-11-30 06589980 bus:OrdinaryShareClass1 2025-11-30 06589980 bus:OrdinaryShareClass1 2024-11-30 06589980 bus:OrdinaryShareClass2 2025-11-30 06589980 bus:OrdinaryShareClass2 2024-11-30 06589980 bus:OrdinaryShareClass3 2025-11-30 06589980 bus:OrdinaryShareClass3 2024-11-30 06589980 bus:AllOrdinaryShares 2025-11-30 06589980 bus:AllOrdinaryShares 2024-11-30 06589980 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 06589980 bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 06589980 bus:FRS102 2024-12-01 2025-11-30 06589980 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 06589980 bus:Director1 2024-12-01 2025-11-30 06589980 bus:Director2 2024-12-01 2025-11-30 06589980 bus:Director3 2024-12-01 2025-11-30 06589980 bus:Director4 2024-12-01 2025-11-30 06589980 bus:FullAccounts 2024-12-01 2025-11-30 xbrli:pure xbrli:shares iso4217:GBP